Last reviewed · How we verify
HAART
At a glance
| Generic name | HAART |
|---|---|
| Also known as | Any ART, ARM 1, ARM 2, ARM 3, Triumeq, Dovato, Highly active antiretrovial therapy (HAART) |
| Sponsor | Cantonal Hospital of St. Gallen |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Extended Follow-Up of the ISS T-003 Trial Volunteers (ISS T-003 EF-UP2020)
- Quality of Life, Depression and Sexual Function in Men Living With HIV
- Boosting the HRQoL Among HIV+ Mothers and Children (NA)
- Efficacy and Safety of Doravirine in the Rapid Initiation (PHASE4)
- Towards a More Standardized Bicuspid Aortic Valve Repair: Rationale and Design of CONTOUR Trial - a Randomized Trial (NA)
- Optimizing Care for Challenging People Living With HIV (NA)
- The University of Zimbabwe College of Health Science (UZ-CHS) BIRTH COHORT Study
- Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HAART CI brief — competitive landscape report
- HAART updates RSS · CI watch RSS
- Cantonal Hospital of St. Gallen portfolio CI